A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma
A phase 1/2 trial of TNB-383B in multiple myeloma, run by AbbVie, active and no longer recruiting.
Overview
A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma is a phase 1/2 interventional study registered as NCT03933735 by AbbVie, with 220 participants enrolled, started 2019-06-24 and due to reach its primary completion in 2026-05. Interventions recorded: TNB-383B.
Similar pages
not linked directly; found by shared links- TrialHuman BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM
Shares Multiple myeloma and the tag pipeline.
- TrialA Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.
- TrialStudy of ODX (OsteoDex) in Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.
- TrialA Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.
- TrialA Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Shares AbbVie (incl. ImmunoGen, Capstan) and the tag pipeline.
- TrialSARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
Shares Multiple myeloma and the tag pipeline.
- TrialA Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.
- TrialA Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan
Shares AbbVie (incl. ImmunoGen, Capstan) and the tag pipeline.